MedPath

A clinical study to evaluate efficacy & safety of a novel nasal spray fixed dose combination of Azelastine hydrochloride & Mometasone furoate monohydrate compared with individual Azelastine hydrochloride 137mcg & Mometasone Monohydrate 50mcg nasal spray in patients with perennial Allergic Rhinitis.

Phase 3
Completed
Conditions
Health Condition 1: null- Patients suffering from Perennial allergic Rhinitis
Registration Number
CTRI/2014/02/004439
Lead Sponsor
Cipla Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

1. An Ethics committee approved Informed Consent Form signed and

dated by subject and or LAR before screening procedures.

2. Subjects of either sexes between 18 and 55 years of age with at least

1 positive response to air allergen in skin prick test at screening and a

history of perennial allergic rhinitis.

3. Subjects presenting with moderate to severe symptoms of perennial

allergic rhinitis (nasal and/or ocular)

4. In the opinion of the investigator, subject able to comply with

requirements of Protocol.

Exclusion Criteria

1. Subjects with history of severe physical nasal obstruction or injury,

nasal ulcers, nasal polyps, significant deviated nasal septum, recent

nasal surgery, asthma, COPD, rhinitis medicamentosa, acute or

chronic sinusitis, glaucoma, cataract, any psychiatric disorder,

adrenal insufficiency and contact lens wearers.

2. Subjects with bacterial, viral or fungal infection within 2 weeks prior to

screening visit.

3. Subjects with known hypersensitivity to all study medicines

4. Subjects with history of alcohol or drug abuse

5. Subjects who have participated in clinical trial in past 30 days

6. Pregnant or lactating mothers or planning to become pregnant

7. Any clinically significant lab values as per investigators discretion

8. Subjects suffering from significant uncontrolled disease of any body

system

9. Use of anti-allergic immunotherapy or biologicals within past 2 years

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath